Piper Jaffray analyst Joseph Catanzaro noted that Catalyst Pharmaceuticals announced on a call this morning that the estimated annual price of Firdapse per Lambert-Eaton Myasthenic Syndrome patient will be $375,000 based on the average stable dose achieved during its studies. He believes this is well-above investor expectations and may even see some push back, but still thinks doctors will "readily prescribe" the drug if it is covered by payers. Citing the higher than expected price, Catanzaro raised his price target on Catalyst shares to $7.50 from $5.00 and keeps an Overweight rating on the stock.